Kewaunee Scientific (KEQU) Current Deferred Revenue (2011 - 2026)

Kewaunee Scientific's Current Deferred Revenue history runs 16 years deep, the most recent figure standing at $4.2 million for Q2 2026.

• On a quarterly basis, Current Deferred Revenue fell 31.63% year-over-year to $4.2 million in Q2 2026; TTM through Apr 2026 was $4.2 million, a 31.63% decrease from a year earlier, with the FY2026 full-year figure at $4.2 million, down 31.63% from the prior year.
• Current Deferred Revenue rose to $4.2 million in Q2 2026 per KEQU's latest filing, from $4.1 million in the prior quarter.
• Across five years, Current Deferred Revenue topped out at $14.1 million in Q3 2022 and bottomed at $3.1 million in Q1 2022.
• The 5-year median for Current Deferred Revenue is $5.0 million (2024), against an average of $6.1 million.
• Across the five-year window, Current Deferred Revenue surged 452.49% in 2022 and slumped 56.84% in 2023, its largest moves.
• Year by year, Current Deferred Revenue stood at $11.4 million in 2022, then slumped by 56.84% to $4.9 million in 2023, then gained by 26.83% to $6.2 million in 2024, then tumbled by 30.41% to $4.3 million in 2025, then slipped by 4.38% to $4.2 million in 2026.
• Per Business Quant, the three latest KEQU Current Deferred Revenue figures stand at $4.2 million (Q2 2026), $4.1 million (Q1 2026), and $4.3 million (Q4 2025).